Our partner Signos was featured in a review examining how continuous glucose monitors (CGMs) are increasingly being used beyond diabetes management to support healthier lifestyle choices and weight loss. The article highlights Signos as an FDA-cleared, AI-enabled system that combines real-time glucose monitoring with personalized insights to help users better understand how food, exercise, stress, and daily habits affect metabolic responses.
By pairing CGM data with AI-driven recommendations and behavioral nudges, Signos aims to transform glucose insights into actionable changes. The coverage underscores growing clinical and consumer interest in CGM-based weight management, positioning Signos at the intersection of health technology, metabolic awareness, and personalized wellness.